Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Jazz Pharmaceuticals plc | EVP, Global Head of R&D | Ordinary Shares | 62.2K | $7.31M | $117.53 | Mar 5, 2024 | Direct |
iTeos Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 24.2K | Jun 11, 2024 | Direct | ||
Jounce Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 0 | May 3, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ITOS | iTeos Therapeutics, Inc. | Jun 11, 2024 | 1 | $0 | 4 | Jun 13, 2024 | Director |
JAZZ | Jazz Pharmaceuticals plc | Mar 5, 2024 | 1 | -$505K | 4 | Mar 7, 2024 | EVP, Global Head of R&D |
JAZZ | Jazz Pharmaceuticals plc | Mar 1, 2024 | 1 | $0 | 4 | Mar 5, 2024 | EVP, Global Head of R&D |
JAZZ | Jazz Pharmaceuticals plc | Jan 17, 2024 | 2 | -$206K | 4 | Jan 19, 2024 | EVP, Global Head of R&D |
ITOS | iTeos Therapeutics, Inc. | Jun 13, 2023 | 1 | $0 | 4 | Jun 15, 2023 | Director |
JAZZ | Jazz Pharmaceuticals plc | Jun 5, 2023 | 1 | -$170K | 4 | Jun 7, 2023 | EVP, Global Head of Research a |
JNCE | Jounce Therapeutics, Inc. | May 3, 2023 | 4 | $0 | 4 | May 4, 2023 | Director |
JAZZ | Jazz Pharmaceuticals plc | Mar 3, 2023 | 2 | -$325K | 4 | Mar 7, 2023 | EVP, Global Head of Research a |
JAZZ | Jazz Pharmaceuticals plc | Dec 9, 2022 | 1 | -$279K | 4 | Dec 13, 2022 | EVP, Global Head of R&D |
JNCE | Jounce Therapeutics, Inc. | Jun 24, 2022 | 1 | $0 | 4 | Jun 28, 2022 | Director |
ITOS | iTeos Therapeutics, Inc. | Jun 9, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director |
JAZZ | Jazz Pharmaceuticals plc | Jun 6, 2022 | 1 | -$193K | 4 | Jun 8, 2022 | EVP, Global Head of R&D |
JAZZ | Jazz Pharmaceuticals plc | Mar 3, 2022 | 2 | -$204K | 4 | Mar 9, 2022 | EVP, Global Head of R&D and Ch |
JNCE | Jounce Therapeutics, Inc. | Jun 18, 2021 | 1 | $0 | 4 | Jun 22, 2021 | Director |
ITOS | iTeos Therapeutics, Inc. | Jun 17, 2021 | 1 | $0 | 4 | Jun 21, 2021 | Director |
JAZZ | Jazz Pharmaceuticals plc | Jun 5, 2021 | 1 | -$213K | 4 | Jun 9, 2021 | EVP R&D, Chief Medical Officer |